How to Verify a Legitimate GLP-1 Provider

Direct answer

To verify a GLP-1 provider, start with the basics: confirm that a licensed clinician is involved, check whether the provider can legally care for patients in your state, understand what medical evaluation happens before prescribing, ask how side effects and follow-up are handled, and confirm whether the medication being discussed is an FDA-approved product or a compounded product.

Whether a GLP-1 medication is right for you requires clinician evaluation. Provider rankings and recommendations for a specific clinic, telehealth service, pharmacy, or medication should not replace transparency checks, care standards, and red-flag review.

Confirm the clinician and license

A legitimate GLP-1 provider should make it possible to understand who is providing clinical care. That does not always mean every clinician is listed on a marketing homepage, but the service should be able to identify the clinician or clinical group responsible for evaluation, prescribing, follow-up, and urgent questions.

If a service sells medication but does not clearly explain who evaluates you, where they are licensed, or how clinical follow-up works, treat that as a warning sign.

• Look for clinician name, credentials, specialty or clinical background, and state eligibility information.
• Understand whether care is delivered by a physician, nurse practitioner, physician assistant, registered dietitian, pharmacist, care team, or another role.
• Confirm there is a way to contact the care team after the initial visit.

Understand the medical evaluation

Prescription weight-management care should not be treated like buying a supplement online. A provider should ask enough questions to decide whether further evaluation is appropriate and whether a medication discussion should continue.

A GLP-1 evaluation may include discussion of medical history, current medications, weight history, diabetes or metabolic conditions, pregnancy or pregnancy plans, gastrointestinal history, gallbladder or pancreatic history, kidney concerns, prior medication reactions, and other factors that could affect safety. The exact evaluation belongs to the clinician.

Ask how follow-up works

GLP-1 care does not end when a prescription is written. Readers should understand how a provider handles follow-up, refill review, ongoing questions, adverse symptoms, and care coordination.

The goal is to make sure the provider has a clear process, while leaving personal medical decisions with licensed clinicians.

• How often is follow-up expected?
• Who answers medication questions after the visit?
• What should I do if side effects become severe or unusual?
• What symptoms require urgent medical care rather than a portal message?
• How are refills reviewed?
• Does the provider discuss nutrition, protein, hydration, fiber, physical activity, and muscle preservation in a way that is tailored to the patient?

Confirm the medication source

Ask whether the medication being discussed is an FDA-approved product, a compounded product, or something else. This question is basic, and a legitimate provider should answer it directly.

FDA-approved GLP-1 and related medications have product-specific labels and indications. Compounded GLP-1 products are not FDA-approved. Do not assume that a product is FDA-approved because marketing uses familiar medication names, ingredient names, generic wording, or before-and-after images.

Be careful with compounded-product claims

Compounded medications can have a role in healthcare when specific legal and clinical conditions are met, but compounded GLP-1 products should not be presented as ordinary generic versions of FDA-approved brand medications.

FDA has said compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. FDA has also warned about compounded injectable semaglutide dosing errors, including errors involving multiple-dose vials and unit conversions.

• Be cautious with claims that compounded products are FDA-approved, generic, identical, equivalent, or clinically proven to match an FDA-approved brand without appropriate evidence and caveats.
• Be cautious if the service avoids naming the dispensing pharmacy or uses research-use, peptide, or not-for-human-consumption language.
• Be cautious with syringe-unit conversions or dose-adjustment instructions in marketing material.

Treat retatrutide claims as a separate red flag

Retatrutide is investigational and is not FDA-approved as a prescription product. Source-dated education about research status is different from clinical use, purchasing, compounding, prescribing, dosing, or provider access.

If a provider, clinic, pharmacy, telehealth service, or peptide vendor claims that retatrutide is available for prescription, compounding, purchase, provider access, or personal use, treat that as a major warning sign. FDA has separately warned about unapproved GLP-1 drugs used for weight loss.

Before a clinical conversation

Before a clinician or pharmacist conversation, identify the exact product, active ingredient, approval status, warning topics, and source questions that matter.

Medication choice, dosing, pharmacy selection, and treatment planning require a licensed clinician who can evaluate medical history, contraindications, monitoring needs, other medications, pregnancy plans, and current product labeling.

Care decisions belong with clinicians

Changing medication, managing symptoms, preparing injections, and interpreting a personal risk profile require clinician or pharmacist guidance.

Product labels, pharmacist counseling, and clinician follow-up remain the controlling sources for patient-specific decisions.

Source limits

Approval status, compounding policy, shortage status, product labels, and trial status can change. The current source date matters when reading high-change medical or regulatory claims.

Trial evidence applies to the studied population and endpoint. It is not a promise of an individual result.

Red-flag checklist

Consider slowing down or looking for another source of care if a service shows one or more of these warning signs.

• It does not identify the clinician or clinical group involved.
• It promises approval before meaningful clinical evaluation.
• It treats prescription medication as a simple product checkout.
• It uses guaranteed weight-loss claims.
• It markets compounded products as FDA-approved or generic equivalents.
• It promotes retatrutide access, purchase, pharmacy availability, or compounding.
• It hides subscription terms, medication costs, pharmacy source, or affiliate relationships.

Questions